AbbVie EVP granted options and performance stock

AbbVie Inc. executive Demetris D. Crum, EVP and Chief HR Officer, reported equity compensation awards rather than open-market trades.

Rhea-AI Filing Summary

AbbVie Inc. executive Demetris D. Crum, EVP and Chief HR Officer, reported equity compensation awards rather than open-market trades. On February 18, 2026, Crum was granted options for 13,406 shares of AbbVie common stock under the AbbVie Amended and Restated 2013 Incentive Stock Program. These options become exercisable in three annual installments of 4,469 shares on February 18, 2027, 4,469 shares on February 18, 2028, and 4,468 shares on February 18, 2029.

Crum also acquired 1,216 shares and 1,244 shares of AbbVie common stock tied to performance-vesting restricted stock unit awards originally granted on February 15, 2024 and February 13, 2025, respectively. These awards vest based on a relative return on equity measure, with performance certified by AbbVie’s Compensation Committee, and the shares are scheduled to be issued on February 28, 2026.

Insider Trade Summary

Grant/Award: 15,866 shares

Grant/Award 3 txns

Insider Crum Demetris D

Role EVP, CHIEF HR OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Option (Right to buy)	13,406	$0.00	$0.00
Grant/Award	Common Stock, $0.01 par value	1,216	$0.00	$0.00
Grant/Award	Common Stock, $0.01 par value	1,244	$0.00	$0.00

Holdings After Transaction: Option (Right to buy) — 13,406 contracts (Direct); Common Stock, $0.01 par value — 9,508 shares (Direct)

Footnotes (3)

1. F1. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
2. F2. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
3. F3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,469 on February 18, 2027, 4,469 on February 18, 2028, and 4,468 on February 18, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did AbbVie (ABBV) executive Demetris Crum report?

Demetris Crum reported equity awards, not open-market trades. He received options for 13,406 AbbVie shares and two performance-based restricted stock unit awards totaling 2,460 shares, all granted or vesting based on AbbVie’s incentive and performance programs.

Were the AbbVie (ABBV) insider transactions by Demetris Crum open-market buys or compensation grants?

The transactions are compensation grants, not open-market buys. They include stock options and performance-vesting restricted stock units awarded under AbbVie’s incentive plans, reflecting executive compensation tied to performance metrics rather than discretionary share purchases.

How many AbbVie (ABBV) options were granted to Demetris Crum in this filing?

Demetris Crum was granted options for 13,406 AbbVie shares. These options were issued under the AbbVie Amended and Restated 2013 Incentive Stock Program, forming part of his long-term equity compensation package as an executive officer.

What are the vesting dates for Demetris Crum’s new AbbVie (ABBV) stock options?

The options vest in three annual installments. They become exercisable for 4,469 shares on February 18, 2027, another 4,469 shares on February 18, 2028, and 4,468 shares on February 18, 2029, reflecting a multi-year retention structure.

What performance conditions apply to Demetris Crum’s AbbVie (ABBV) restricted stock units?

The restricted stock units vest based on a relative return on equity measure. Performance is assessed and certified by AbbVie’s Compensation Committee, and only after goal attainment are vesting restrictions released and shares scheduled for issuance to the executive.

When will the performance-based AbbVie (ABBV) shares be issued to Demetris Crum?

The performance-based shares are scheduled to be issued on February 28, 2026. This applies to shares tied to restricted stock unit awards granted in February 2024 and February 2025, following certification that the specified performance goals were achieved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 06:35 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crum Demetris D

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CHIEF HR OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	02/18/2026		A		1,216(1)	A	$0	8,264	D
Common Stock, $0.01 par value	02/18/2026		A		1,244(2)	A	$0	9,508	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to buy)	$230.04	02/18/2026		A		13,406		(3)	02/17/2036	Common Stock	13,406	$0	13,406	D

Explanation of Responses:

1. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

2. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

3. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,469 on February 18, 2027, 4,469 on February 18, 2028, and 4,468 on February 18, 2029.

	/s/ T.O. Odutayo, Attorney-in-Fact for Demetris D. Crum	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.